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Abstract We have isolated NIH-3T3 cell lines overexpressing
the nuclear 24-kDa isoform of fibroblast growth factor (FGF)-2
and characterized its regulatory effect on the expression of
interleukin-6 (IL-6) in these cells. The clone pRF5 expressing the
highest level was able to grow in 1% serum medium to a high
saturation density and acquired a radioresistance advantage. In
pRF5 and another clone pRF1, IL-6 RNA levels were markedly
increased. Studies with IL-6 promoter constructs revealed that
IL-6 gene up-regulation occurred at the transcriptional level and
did not involve the AP-1 binding site. Exogenously added 18-kDa
isoform of FGF-2 (100 ng/ml) produced down-regulation of IL-6
involving an AP-1 binding site, thus suggesting a receptor-
independent pathway for the intracellular 24-kDa isoform.
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1. Introduction
Basic ¢broblast growth factor (FGF-2) is a multifunctional
cytokine involved in the proliferation and di¡erentiation of a
broad spectrum of mesodermal and neuro-ectodermal cell
types [1]. It has been also implicated in angiogenesis [2] and
injury-repair responses.
Di¡erent molecular forms of FGF-2, representing alterna-
tive translation products from a single mRNA, have been
characterized [3]. Initiation of translation at CUG codons
located 5P to the AUG codon accounts for the 24-, 22.5-
and 22-kDa isoforms, whereas the AUG codon is used to
generate an 18-kDa protein. The small isoform is mainly cy-
toplasmic and when secreted, subsequently activates the FGF
receptor pathway [4] eliciting the cascade of second messenger
production. The high molecular weight isoforms of FGF-2
(HMW FGF-2) are NH2-terminal extensions of the 18-kDa
form and contain nuclear localization sequence-like signals
responsible for their preferential nuclear targeting [5]. Accord-
ingly, the biological speci¢city of the di¡erent isoforms of
FGF-2 might depend upon the subcellular localization of
these molecules and their ability to be secreted and to activate
a membrane receptor.
Although there is an increasing amount of published data
relating to a speci¢c intracellular mode of action of HMW
FGF-2, the mechanisms by which these FGF-2 molecules
produce their speci¢c activities is not clear. They may act as
transcription factors [6,7] or indirectly by forming complexes
with transcription factors or other intracellular partners [8].
Indeed, the secreted 18-kDa isoform which acts in a receptor-
dependent manner, can modulate gene transcription in a cell-
free system [7], emphasizing that the FGF-2 core can act in
vivo in the nucleus at the promoter level.
In addition to its subcellular location [5] and a⁄nity for
DNA [6], there is also evidence to suggest that some of the
biological activities of HMW FGF-2 are speci¢cally receptor-
independent. For instance, it has been shown that the expres-
sion of di¡erent forms of FGF-2 results in di¡erent NIH-3T3
transformed cell phenotypes [9]. These observations have been
con¢rmed in FGF-2 transfected ABAE cells where the nuclear
HMW FGF-2 isoforms induce immortalization and the cyto-
plasmic 18-kDa form is transformant [10]. Moreover, in
agreement with the oncogenic theory, the coexpression of
these forms allowed a typical malignant transformation [10].
Therefore, to understand how cellular responses to HMW
FGF-2 are produced, our e¡orts have been focused on the
study of stably transfected cell models and the subsequent
expression of genes such as interleukin-6 (IL-6) gene whose
products are possibly related to the growth factor activity [11^
14].
We report here the existence of two distinct pathways for
FGF-2-induced IL-6 gene regulation in NIH-3T3 cells. The
AP-1 binding motif on the IL-6 promoter is not required for
induction by the intracellular 24-kDa isoform, but is necessary
for the down-regulation of IL-6 expression by the extracellu-
lar 18-kDa isoform.
2. Materials and methods
2.1. Materials
Rabbit polyclonal anti-bFGF antibody (Ab-2) was purchased from
Oncogene Science (Paris, France). Recombinant FGF-2 was produced
in our laboratory. Molecular biology reagents, newborn calf serum
(CS) and Dulbecco’s medium without phenol red were from Gibco-
BRL, Gaithersburg, USA. Amphotericin B, gentamicin and L-gluta-
mine were from Seromed, Biochrom, Berlin, Germany. Cells were
irradiated with a clinical cobalt-60 machine (Theratronics 1000;
AECL, Ottawa, Canada).
2.2. Cell culture and transfection
NIH-3T3 cells were grown in DME containing either 10% or 1%
calf serum medium supplemented with amphotericin B (2.5 Wg/ml),
gentamicin (50 Wg/ml) and L-glutamine (2 mM) and incubated at
37‡C, 5% CO2. The cells were transfected with Lipofectin Reagent
(Gibco-BRL), either with the eukaryotic bicistronic expression control
pEN vector [15], or with pRFGF24 vector which is similar to pEN
but contains a cDNA insert where the CUG305 of FGF-2 was mu-
tated in AUG, allowing the synthesis of the 24-kDa FGF-2 isoform
only. The cells were cultured in DME containing 10% CS plus 1 mg/
ml geneticin (G418: Gibco-BRL). After two weeks, G418-resistant
clones were isolated and subcloned in 35-mm dishes. These G418-
resistant cells were ampli¢ed and then analyzed for their recombinant
FGF-2 in Western blotting as described below.
2.3. Western blot analysis
Frozen cell pellets were treated and 30 Wg of total protein was
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analyzed as previously described [15] for FGF-2 detection with a
rabbit polyclonal anti-FGF-2 antibody (Ab-2; diluted 1:200) and
horseradish peroxidase-labeled anti-rabbit IgG (Amersham) diluted
1:10 000. For L-actin detection, the same nitrocellulose membranes
were rinsed overnight in TBST (10 mM Tris-HCl, pH 8.0, 150 mM
NaCl, 0.2% Tween 20), reblocked for 1 h in TBST supplemented with
3% non-fat milk, and treated with a monoclonal mouse anti-L-actin
antibody (1:120 000; Sigma-Aldrich) and an anti-mouse HRP anti-
body (Sigma-Aldrich) diluted 1:5000.
2.4. Cell proliferation assays
Cells were seeded at 7000 cells/well in 12-well culture dishes in 10%
CS DME medium. After overnight incubation at 37‡C, and then every
three days, cells were rinsed twice with PBS and refed with DME
without phenol red containing 1% CS. The cells were counted with
a Coulter counter (Coulter Electronics, Hialeah, FL, USA) every
three days. All experiments were performed twice in triplicate.
2.5. Radiation survival curves
Cells were plated at a density of 2000 cells/25 cm2 in fresh medium.
After 48 h incubation, irradiation was carried out with a clinical
cobalt-60 machine at a dose rate of 65 cGy/min. Single doses ranging
from 1 to 10 Gy were delivered and the cells were returned to the
incubator for one week. Survival after irradiation was calculated as
previously described [16] as the ability of the cells to maintain their
clonogenicity.
2.6. RNA isolation and RNase protection
Total RNA was isolated from appropriately treated cells by use of
Rneasy columns from Qiagen. RNase protection assays were per-
formed with the RiboQuant System and the mck-1 mouse cytokine/
chemokine set from Pharmingen (San Diego, CA, USA), using 15 Wg
of total RNA for each experiment. Assays were quantitated with a
Molecular Dynamics PhosphorImager and IL-6 mRNA signal inten-
sity was normalized to the GAPDH housekeeping gene signal.
2.7. Cell cotransfections and luciferase activity assays
Cells were plated at a density of 50 000 cells/well in 6-well culture
plates. Twenty-four hours later, medium was changed to 1% CS
DME. After another 24-h incubation, cells were transfected with the
indicated doses of plasmid vectors with the Fugene 6 transfection
reagent (Boehringer Mannheim) following the manufacturer’s instruc-
tions. The reporter plasmid prIL-6 was obtained by insertion of the
human IL-6 DNA fragment 31158 to +11 released by XbaI and XhoI
digestion of the plasmid pBRgHIL-61 (kindly supplied by Walter
Fiers, Laboratory of Molecular Biology, University of Gent, Belgium)
into pGL3-Basic vector (Promega, Madison, WI, USA) which was
digested by NheI and XhoI. The pRL-CMV Renilla reporter vector
from Promega was used as an internal control of transfections. The
Bluescript II KS vector (Stratagene, La Jolla, CA, USA) was added to
adjust the transfected DNA amounts to 5 Wg. After 24 h, the cells
were replaced in 1% CS medium containing or not recombinant FGF-
2 to various doses. Luciferase activities in the lysate were determined
48 h later using the Dual-Luciferase Reporter Assay System from
Promega. The activity of the ¢re£y luciferase experimental reporter
(PrIL-6 or PrIL-6vAP1) was normalized to the activity of this internal
control. The luciferase activity measurements were performed with a
plate-reading luminometer (Labsystems Luminoskan). All values are
expressed as mean þ S.D. Unpaired Student’s tests were employed to
determine the signi¢cance of changes. A signi¢cant di¡erence was
taken for P values 6 0.05.
3. Results
3.1. Construction and characterization of NIH-3T3 cell lines
stably expressing the 24-kDa isoform of FGF-2
The bicistronic vector pRFGF24 coding for the high mo-
lecular weight isoform of FGF-2 [10], and the pEN control
vector were transfected into NIH-3T3 cells. From 15 G418-
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Fig. 1. 24-kDa FGF-2 stably transfected cell lines: pRF1 and pRF5. A: FGF-2 protein expression from vector alone and pFGF24 transfected
NIH-3T3 cells. Thirty micrograms of extracted proteins from each cell line were loaded on 12.5% SDS polyacrylamide gels, and Western blot-
ting was performed as described in Section 2. Arrows indicate the positions for the 24-kDa FGF-2 and L-actin proteins. Under the same condi-
tions, no recombinant 24-kDa species of FGF-2 can be detected in wild-type (not shown) or in vector-transfected 3T3 cells, pEN. B: Morpho-
logical changes induced by transfection with the 24-kDa FGF-2 cDNA depending on the recombinant protein content.
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resistant clones isolated, we selected two representative
pRFGF24-transfected clones expressing FGF-2 at a di¡erent
level.
As shown by Western blot using anti-FGF-2 antibody (Fig.
1A), pRF5 and pRF1 express the recombinant 24-kDa iso-
form at high level in a ratio of 2.5:1, respectively. The amount
of endogenously overexpressed FGF-2 is about 1 ng/mg pro-
tein for pRF5. We carried out subcellular compartmentaliza-
tion studies by immunocytochemical analysis and con¢rmed
the preferential nuclear and perinuclear localization of FGF-2
in pRF5 cells (data not shown).
FGF-2 transfected cells are morphologically di¡erent from
vector alone transfected cells (Fig. 1B). In low serum medium,
the control cells are polygonal, fusiform and refractile. With
increasing levels of recombinant FGF-2, the cells become larg-
er and better organized.
To further characterize these cells, we performed prolifera-
tion tests with clones expressing the 24-kDa FGF-2 protein
and vector alone-transfected cells in culture medium contain-
ing 1% calf serum. Fig. 2A shows typical proliferation curves
with two representatives clones pRF1 and pRF5. At early
time points, we observed a growth disadvantage for pRF5
which might result from a low plating e⁄ciency and the
need of cell to cell contacts for NIH-3T3 growth. As previ-
ously described, using adenoviral FGF-2 coding vector [17],
we found that the overexpressed 24-kDa isoform of FGF-2
confers a high saturation density growth of pRF5 cells as well
as the ability to grow in low serum medium compared to the
pEN mocked transfected cells. Similarly, the pRF1 cells, ex-
pressing lower levels of the recombinant growth factor, dis-
played a proliferative advantage compared to pEN, but
reached a density to saturation identical to the one observed
for the control cells.
It has recently been described that the endogenously ex-
pressed 24-kDa isoform of FGF-2 confers a selective advant-
age to Q-radiation of transfected HeLa cells [16]. Fig. 2B
shows representative clonogenic survival curves of pRF5
and pEN cells exposed to graded doses of radiation. The
pRF5 cells displayed a signi¢cant increase in clonogenic sur-
vival compared with the pEN cells (P6 0.01). The mean in-
activation dose (MID) was 182 þ 18 cGy for pEN and
410 þ 36 cGy for pRF5. We also veri¢ed that the endogenous
murine isoforms levels of FGF-2 were not modi¢ed under
these transfection conditions (data not shown).
3.2. Constitutive overexpression of recombinant 24-kDA FGF-2
up-regulates the amount of interleukin-6 mRNA
As a strong relationship exists between FGF-2 and IL-6
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Fig. 2. The biological activities of 24-kDa FGF-2 transfected NIH-
3T3 cells. A: Proliferation of cells expressing 24-kDa FGF-2 with
two di¡erent levels: pRF1 and pRF5, compared to mocked trans-
fected cells : pEN. The experiment was carried out as described in
Section 2. The data represent mean þ S.D. of triplicate samples and
are representative of two independent experiments. B: Radiation
survival curves of pRF5 and pEN cells exposed to various ionizing
radiation doses. The radiosensitivity of the di¡erent cell lines was
calculated using the clonogenic survival assay. Data represent a typ-
ical curve from three di¡erent experiments for each clone.
Fig. 3. Activation of IL-6 mRNA expression by endogenous 24-kDa
FGF-2. Fifteen Wg of total RNA from pEN, pRF1 and pRF5 cells
were used for each hybridization experiment. IL-6 and GAPDH
mRNA expression were quantitated simultaneously by RNase pro-
tection as described in Section 2. The autoradiogram shows mRNA
signals for IL-6 and GAPDH in the di¡erent cell lines and a quanti-
tative analysis of the RPA results normalized to the GAPDH
mRNA level was performed with a phosphorimager. Data are pre-
sented in arbitrary units and are means of two experiments sharing
similar results.
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[11^13,18^20], we further investigated the molecular mecha-
nisms involved in the proliferative and radioprotective activ-
ities of HMW FGF-2 by RNase mapping analysis with an
interleukin-6 probe.
Fig. 3 represents the expression pattern for the IL-6 and
GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
mRNAs in control or 24-kDa isoform-transfected NIH-3T3
cells. We have calibrated the level of the interleukin-6 mRNA
amount using the GAPDH mRNA signal as a control. The
relative expression histograms show that IL-6 mRNA levels
increased in transfected cells. In pRF1 cells, IL-6 expression
was enhanced 4-fold when compared to the pEN control cells,
while a 10-fold increase of IL-6 mRNA levels occurred in the
clone pRF5. Consequently, the constitutive expression of this
growth factor up-regulates the intracellular IL-6 mRNA con-
tent in an apparent dose-dependent fashion. This was con-
¢rmed by RT-PCR performed with synthetized speci¢c IL-6
primers (data not shown).
3.3. Stably transfected 24-kDa FGF-2 but not exogenous
FGF-2 up-regulates the interleukin-6 promoter activity
To evaluate whether it was a transcriptional regulation, we
transfected IL-6 reporter constructs in our cells. In the PrIL-6
plasmid, the 5P £anking region (31158 to +11) of the IL-6
gene corresponding to the entire IL-6 promoter [20] was fused
to the ¢re£y luciferase reporter gene, and activation of the IL-
6 promoter was determined by measuring luciferase activity in
transient transfection assays.
As shown in Fig. 4A, the IL-6 promoter activity was up-
regulated and again it was dependent on the amount of re-
combinant FGF-2 expressed in the transfected clones. The
induction was weak for pRF1 and highly signi¢cant
(P6 0.01; t = 5.4) for pRF5. These results suggest that the
di¡erences in interleukin-6 mRNA levels observed in our pre-
vious RNase protection studies very likely re£ect the tran-
scriptional regulation of the IL-6 gene.
Exposure to exogenous 18-kDa FGF-2 enhanced the IL-6
gene expression in several cellular systems, such as human
microvascular endothelial cells [13] and osteoblasts [21]. We
investigated therefore whether the up-regulation observed
with pRF1 and pRF5 cells was due to extracellular release
of the growth factor. Accordingly, we tested di¡erent amounts
of the 18-kDa isoform on the IL-6 promoter regulation. In-
terestingly, as shown in Fig. 4B, large amounts of the growth
factor (up to 100 ng/ml) led to a signi¢cant down-regulation
of the IL-6 promoter (P6 0.01; t = 8.4). Thus, the IL-6 pro-
moter up-regulation described for the pRF1 and pRF5 cells is
not due to an extracellular release of the growth factor.
To further demonstrate that the opposing e¡ects of the 24-
kDa isoform was not as a result of the integration site of the
transfected plasmid, we performed transitory cotransfection
assays with increasing amounts of the pRFGF24 24-kDa
FGF-2 coding vector and PrIL-6 vector. The total transfected
DNA level was standardized with a neutral plasmid pKSII to
avoid any e¡ect of the DNA levels in our studies. IL-6 pro-
moter activity was up-regulated by transiently transfected 24-
kDa FGF-2, reaching signi¢cance when the 3 Wg pRFGFG24/
ml transfection medium was used (P6 0.05; Fig. 4C), thus
con¢rming the results obtained with pRF cells.
3.4. Distinct pathways involved for exogenous and endogenous
FGF-2
As our results suggested distinct signal transduction path-
ways for exogenous and endogenous FGF-2, we analyzed
whether the same regulatory elements were involved in this
di¡erential activity.
We constructed a 5P deletion mutant (positions 3224 to
+11) of the IL-6 promoter which results in removal of the
AP-1 (c-Fos and c-Jun) binding motif. Our transfection ex-
periments showed that deletion of the AP-1 site resulted in a
major decrease of the basal level of the IL-6 promoter activity
(approx. 6-fold, data not shown), con¢rming that the AP-1
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Fig. 4. E¡ects of FGF-2 on the activity of IL-6 promoter. A: pEN, pRF1 and pRF5 NIH-3T3 cells were transiently transfected with 1 Wg
prIL-6 and 40 ng pRL-CMV vectors per well in 6-well culture plates, as explained in Section 2. The relative ¢re£y luciferase activity is the ac-
tual IL-6 promoter activity when calibrated against the Renilla luciferase signal which is representative of the transfection e⁄ciency for each ex-
periment. Results are presented in percentage of the relative ¢re£y luciferase activity in the control pEN cells. *Statistically signi¢cant variations
with P6 0.01. B: NIH-3T3 cells were transfected as below, with prIL-6 and pRL-CMV vectors. Twenty-four hours after transfection, various
doses of FGF-2 were added to the cell low serum medium during an additional 24 h. Data shown are means and standard deviations for tripli-
cate measurements from one representative transfection. *Statistically signi¢cant (P6 0.01). C: NIH-3T3 cells were transiently cotransfected
with 1 Wg pIL-6 as the reporter vector, 0^3 Wg pRFGF24 as the inducer vector and 3^0 Wg pKSII to adjust the amount of DNA to 5 Wg in
each transfection experiment. Forty ng pRL-CMV (Promega) was included in each case as an internal control. Data shown are means and
standard deviations for triplicate luciferase measurements from one representative transfection. *Signi¢cant variation, P6 0.01.
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sequence is essential for the constitutive expression of the IL-6
gene.
Fig. 5A shows the results obtained when pRF1 and pRF5
cells were transiently transfected with the PrIL-6vAP1 report-
er vector. The deletion of AP-1 site did not modify the up-
regulation of luciferase activity (P6 0.01). The more e¡ective
and dose-independent stimulation of the promoter might be
related to the drastic decrease of basal activity for the AP-1
deleted constructs.
Interestingly, the inhibition of promoter activity containing
the AP-1 deletion by the 18-kDa isoform was totally abol-
ished (see Fig. 5B). These results suggest that the AP-1 bind-
ing site regulatory element is necessary for the down-regula-
tion of the promoter activity by the extracellular growth
factor.
4. Discussion
FGF-2 is synthesized as di¡erent molecular weight isoforms
with multiple biological functions depending on their local-
ization in speci¢c cell compartments. As an approach to the
study of the functional properties of intracellular HMW FGF-
2, we have established permanent cell lines that express the
recombinant 24-kDa isoform which is not secreted and mainly
localized in the cell nucleus [6,22^25].
Depending on the growth factor content in the cells, we
typically observed either an increase of the proliferation rate
for the pRF1 clone or both a proliferative advantage and a
high density growth at saturation (pRF5 clone) in low serum
medium. Interestingly, transfection of the same isoform with
an adenoviral vector which leads to a very high expression of
the protein, promoted growth to a high saturation density and
enhanced proliferation in low serum [17]. These data suggest
that a high level of the 24-kDa isoform expression is required
to alter the parameters of cell growth.
Besides change in cell growth, overexpression of the 24-kDa
isoform factor was also able to confer a decreased sensitivity
to radiation-induced death. A similar e¡ect was recently dem-
onstrated in HeLa cells [16].
FGF-2 and IL-6 have both been implicated in proliferation
of a broad spectrum of cell lines as well as in ionizing radio-
resistance [26^31]. Further support for the link between these
cytokines is the molecular relationship, especially on mRNA
stimulation during tumoral progression [11,12], but also rela-
tive to common inducers, namely interleukin-1 (IL-1) and
tumor necrosis factor-K (TNFK) [18^20]. Interestingly, in hu-
man microvascular endothelial HOME cells, the TNFK-in-
duced stimulation of IL-6 expression is preceded by an in-
crease in FGF-2 isoforms, raising the possibility that this
e¡ect is mediated by these TNFK-inducible FGF-2 molecules
[13]. Therefore the induction of IL-6 gene in the cells trans-
fected by the 24-kDa isoform provides a molecular basis for
the change of cell parameters.
In the latter study [13], addition of an FGF-2 antiserum
only partially decreased this response. Such a result argues
in favor of an intracrinal role for the HMW FGF-2 molecules.
It was thus of interest to show that addition of the extracel-
lular 18-kDa isoform led to a di¡erent regulation of the IL-6
gene in NIH-3T3 cells. Indeed, such opposite e¡ects between
di¡erentially localized FGF-2 isoforms, have already been de-
scribed. Estival et al. [32] provided evidence that the expres-
sion of either the cytosolic 18-kDa or the nuclear-targeted 24-
kDa FGF-2 isoform produced an increase in the cell surface
high a⁄nity receptors, and by contrast, exogenously added
FGF-2 exerted opposite e¡ects resulting in FGF receptor
down-regulation.
As such, we investigated both extra- and intracellular FGF-
2 e¡ects on the regulation of AP-1 site deleted IL-6 promoter.
Indeed, FGF-2 is known to induce early response genes such
as c-jun and c-fos in various cell types [33], and IL-6 expres-
sion can be regulated through at least four transcription fac-
tors [34], notably the activator protein-1 binding element (AP-
1). It was thus interesting to show that deletion of the AP-1
element did not modify the response induced by the 24-kDa
isoform whereas it abrogated the down-regulation induced by
the 18-kDa isoform. Consequently, our data strongly suggest
that the 24-kDa FGF-2-induced up-regulation of IL-6 gene
expression does not occur through the activation of the cell
surface receptor but rather through an intracrine mechanism.
In addition, the opposite e¡ects as well as the di¡erential
regulation of IL-6 expression outline the activation of distinct
intracellular pathways by 18-kDa and 24-kDa isoforms of
FGF-2.
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Fig. 5. E¡ect of the AP-1 site deletion on the regulation of the IL-6
promoter activity by FGF-2. Cells were transfected as before except
the prIL-6vAP-1 vector replaced the prIL-6 vector. A: Regulation
of the AP-1 motif deleted IL-6 promoter by constitutive overexpres-
sion of 24-kDa FGF-2 in pRF1 and pRF5 cells. *Signi¢cant varia-
tion (P6 0.01). B: Regulation of the AP-1 site deleted construct by
increasing doses of exogenous FGF-2. Data represent means and
S.D. for three separate transfection experiments.
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Taken together, our data provide evidence for an intracrine
e¡ect of the overexpressed 24-kDa FGF-2 isoform on IL-6
gene up-regulation. Furthermore, whilst regulating the same
gene, both isoforms display opposite e¡ects and distinct mech-
anisms of regulation. Finally, it is of interest to investigate
further the link between the 24-kDa FGF-2 isoform and IL-
6 in the change in proliferation rate and radiation survival.
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